{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:01:39Z","timestamp":1793948499956,"version":"4.8.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117\/KIT and cytoplasmic CD3 (CD117\/KIT+ ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117\/KIT+ cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117\/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL. (Blood. 2004;104:558-560)<\/jats:p>","DOI":"10.1182\/blood-2004-01-0168","type":"journal-article","created":{"date-parts":[[2004,3,29]],"date-time":"2004-03-29T20:13:04Z","timestamp":1080591184000},"page":"558-560","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":96,"title":["Activating FLT3 mutations in CD117\/KIT+ T-cell acute lymphoblastic leukemias"],"prefix":"10.1182","volume":"104","author":[{"given":"Elisabeth","family":"Paietta","sequence":"first","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo A.","family":"Ferrando","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Bennett","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Racevskis","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard","family":"Lazarus","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Dewald","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Wiernik","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Thomas","family":"Look","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Department of Pediatric Oncology and Eastern Cooperative Oncology Group (ECOG) Statistical Center, Dana-Farber Cancer Institute, Boston, MA; University of Rochester, NY; Ireland Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Rambam Medical Center, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL; and the Eastern Cooperative Oncology Group, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223303343200_REF1","unstructured":"Paietta E. Immunobiology of acute leukemia. In: Wiernik P, Dutcher J, Goldman J, Kyle R, eds. Neoplastic Diseases of the Blood. 4th ed. Cambridge, United Kingdom: Cambridge University Press; 2003: 194-231."},{"key":"2020021223303343200_REF2","unstructured":"Sperling C, Schwartz S, Bu\u0308chner T, Thiel E, Ludwig WD. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica.1997;82: 617-621."},{"key":"2020021223303343200_REF3","doi-asserted-by":"crossref","unstructured":"Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma.1998;30: 459-466.","DOI":"10.3109\/10428199809057558"},{"key":"2020021223303343200_REF4","doi-asserted-by":"crossref","unstructured":"Broudy VC. Stem cell factor and hematopoiesis. Blood.1997;90: 1345-1364.","DOI":"10.1182\/blood.V90.4.1345"},{"key":"2020021223303343200_REF5","doi-asserted-by":"crossref","unstructured":"Bertho J-M, Chapel A, Loilleux S, et al. CD135 (Flk2\/Flt3) expression by human thymocytes delineates a possible role of FLT3-ligand in T-cell precursor proliferation and differentiation. Scand J Immunol.2000;52: 53-61.","DOI":"10.1046\/j.1365-3083.2000.00746.x"},{"key":"2020021223303343200_REF6","doi-asserted-by":"crossref","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood.2002;100: 1532-1542.","DOI":"10.1182\/blood-2002-02-0492"},{"key":"2020021223303343200_REF7","doi-asserted-by":"crossref","unstructured":"Lyman SD, Jacobsen SEW. c-kit ligand and Flt3 ligand: stem\/progenitor cell factors with overlapping yet distinct activities. Blood.1998;91: 1101-1134.","DOI":"10.1182\/blood.V91.4.1101"},{"key":"2020021223303343200_REF8","doi-asserted-by":"crossref","unstructured":"Xu F, Taki T, Eguchi M, et al. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Leukemia.2000;14: 945-947.","DOI":"10.1038\/sj.leu.2401760"},{"key":"2020021223303343200_REF9","doi-asserted-by":"crossref","unstructured":"Nakao M, Janssen JWG, Erz D, Seriu T, Bartram CR. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia.2000;14: 522-524.","DOI":"10.1038\/sj.leu.2401695"},{"key":"2020021223303343200_REF10","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood.2001;97: 2434-2439.","DOI":"10.1182\/blood.V97.8.2434"},{"key":"2020021223303343200_REF11","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell.2003;3: 173-183.","DOI":"10.1016\/S1535-6108(03)00003-5"},{"key":"2020021223303343200_REF12","doi-asserted-by":"crossref","unstructured":"Paietta E, Neuberg D, Bennett JM, et al. Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. Leukemia.2003;17: 1544-1550.","DOI":"10.1038\/sj.leu.2402999"},{"key":"2020021223303343200_REF13","doi-asserted-by":"crossref","unstructured":"Paietta E, Racevskis J, Neuberg D, et al. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR\/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG\/MRC intergroup study E2993. Leukemia.1997;11: 1887-1890.","DOI":"10.1038\/sj.leu.2400836"},{"key":"2020021223303343200_REF14","doi-asserted-by":"crossref","unstructured":"van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia.1999;13: 1901-1928.","DOI":"10.1038\/sj.leu.2401592"},{"key":"2020021223303343200_REF15","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell.2002;1: 75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"2020021223303343200_REF16","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood.2001;97: 2434-2439.","DOI":"10.1182\/blood.V97.8.2434"},{"key":"2020021223303343200_REF17","doi-asserted-by":"crossref","unstructured":"Asnafi V, Beldjord K, Boulanger E, et al. Analysis of the TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood.2003;101: 2693-2703.","DOI":"10.1182\/blood-2002-08-2438"},{"key":"2020021223303343200_REF18","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours: Pathology and Genetics series."},{"key":"2020021223303343200_REF19","unstructured":"Nishii K, Kita K, Miwa H, et al. c-kit gene expression in CD7-positive acute lymphoblastic leukemia: close correlation with expression of myeloid-associated antigen CD13. Leukemia.1992;6: 662-668."},{"key":"2020021223303343200_REF20","doi-asserted-by":"crossref","unstructured":"Valverde LR, Matutes E, Farahat N, et al. C-kit receptor (CD117) expression in acute leukemia. Ann Hematol.1996;72: 11-15.","DOI":"10.1007\/BF00663010"},{"key":"2020021223303343200_REF21","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood.2003; 102: 262-268.","DOI":"10.1182\/blood-2002-10-3221"},{"key":"2020021223303343200_REF22","doi-asserted-by":"crossref","unstructured":"Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia.2003;17: 1738-1752.","DOI":"10.1038\/sj.leu.2403099"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/2\/558\/1699955\/zh801404000558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/2\/558\/1699955\/zh801404000558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:30:44Z","timestamp":1581550244000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/2\/558\/18337\/Activating-FLT3-mutations-in-CD117KIT-Tcell-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,15]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-01-0168","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,15]]}}}